145 related articles for article (PubMed ID: 30793466)
1. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Ruggenenti P; Trillini M; P Barlovic D; Cortinovis M; Pisani A; Parvanova A; Iliev IP; Ruggiero B; Rota S; Aparicio MC; Perna A; Peraro F; Diadei O; Gaspari F; Carrara F; Stucchi N; Martinetti D; Janez A; Gregoric N; Riccio E; Bossi AC; Trevisan R; Manunta P; Battaglia G; David S; Aucella F; Belviso A; Satta A; Remuzzi G;
Diabetes Obes Metab; 2019 May; 21(5):1177-1190. PubMed ID: 30793466
[TBL] [Abstract][Full Text] [Related]
2. Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Ruggenenti P; Cortinovis M; Parvanova A; Trillini M; Iliev IP; Bossi AC; Belviso A; Aparicio MC; Trevisan R; Rota S; Perna A; Peracchi T; Rubis N; Martinetti D; Prandini S; Gaspari F; Carrara F; De Cosmo S; Tonolo G; Mangili R; Remuzzi G;
PLoS Med; 2021 Jul; 18(7):e1003691. PubMed ID: 34260595
[TBL] [Abstract][Full Text] [Related]
3. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
4. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
5. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
6. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.
Stergiou GS; Makris T; Papavasiliou M; Efstathiou S; Manolis A
J Hypertens; 2005 Apr; 23(4):883-9. PubMed ID: 15775795
[TBL] [Abstract][Full Text] [Related]
8. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
Segura J; Praga M; Campo C; Rodicio JL; Ruilope LM
J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
[TBL] [Abstract][Full Text] [Related]
9. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
10. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
[TBL] [Abstract][Full Text] [Related]
11. Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
Suzuki H; Kanno Y; Ikeda N; Nakamoto H; Okada H; Sugahara S
Hypertens Res; 2002 Nov; 25(6):865-73. PubMed ID: 12484510
[TBL] [Abstract][Full Text] [Related]
12. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
13. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Waeber B; Aschwanden R; Sadecky L; Ferber P
J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
[TBL] [Abstract][Full Text] [Related]
15. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
Freedman BI; Wuerth JP; Cartwright K; Bain RP; Dippe S; Hershon K; Mooradian AD; Spinowitz BS
Control Clin Trials; 1999 Oct; 20(5):493-510. PubMed ID: 10503809
[TBL] [Abstract][Full Text] [Related]
16. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
17. Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide.
Lee IT; Sheu WH; Hung YJ; Chen JF; Wang CY; Lee WJ
Dis Markers; 2015; 2015():780743. PubMed ID: 25918454
[TBL] [Abstract][Full Text] [Related]
18. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Bakris GL; Toto RD; McCullough PA; Rocha R; Purkayastha D; Davis P;
Kidney Int; 2008 Jun; 73(11):1303-9. PubMed ID: 18354383
[TBL] [Abstract][Full Text] [Related]
19. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Campbell R; Sangalli F; Perticucci E; Aros C; Viscarra C; Perna A; Remuzzi A; Bertocchi F; Fagiani L; Remuzzi G; Ruggenenti P
Kidney Int; 2003 Mar; 63(3):1094-103. PubMed ID: 12631093
[TBL] [Abstract][Full Text] [Related]
20. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
